id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-4429-0005,FDA,FDA-2018-E-4429,Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Determinations,2019-11-29T05:00:00Z,2019,11,2019-11-29T05:00:00Z,2020-05-28T03:59:59Z,2020-05-25T01:00:37Z,2019-25821,0,0,09000064841c881c
FDA-2018-E-4429-0004,FDA,FDA-2018-E-4429,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-12T04:00:00Z,2019,9,2019-09-12T04:00:00Z,,2019-09-12T20:24:21Z,,0,0,0900006483f4d7ed
FDA-2018-E-4429-0003,FDA,FDA-2018-E-4429,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T18:28:16Z,,0,0,0900006483c734b1